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PREDICTORS OF TREATMENT OUTCOME IN PATIENTS TREATED WITH 
RADICAL CHEMORADIOTHERAPY FOR STAGE III NON-SMALL CELL LUNG 
CANCER 
 
BACKGROUND: Chemoradiation has been well established as standard treatment for stage III 
non-small cell lung cancer (NSCLC). Previous studies have shown that the tumour size as well as 
its metabolic activity predict treatment outcome after definitive treatment for early-stage disease. 
We would like to investigate if there are any clinical and metabolic predictors of treatment 
outcome for stage III NSCLC after chemoradiation. PATIENTS AND METHODS: 56 
consecutive patients (46 males and 10 females) treated with radical concurrent chemoradiation for 
their stage IIIA (n=21) and IIIB (n=35) (AJCC 7th edition) unresectable non-small cell lung 
cancer between July 2006 to February 2012 were retrospectively reviewed. 42 patients had 
positron emission tomography with integrated computed tomography (PET-CT) scan performed 
at diagnosis. Of which 14 patients also had PET-CT scan after induction chemotherapy and 
before concurrent chemoradiation. All received concurrent chemoradiation +/- induction 
chemotherapy and adjuvant chemotherapy. Primary study endpoint was progression-free survival 
(PFS). Secondary endpoints include overall survival (OS), response rate and toxicity. Predictors 
of PFS and OS were investigated in subgroup analyses. RESULTS:  The mean age of this cohort 
was 59.1 years (range 32-77). The dose of radiotherapy ranged from 40.0 to 70.2Gy (median dose 
63.0Gy). 48 (85.7%) patients received induction chemotherapy (mean 2.5 cycles) and 17 (30.4%) 
patients received adjuvant chemotherapy (mean 2.0 cycles). The median PFS and OS were 13.6 
months and 53.5 months respectively, after a median follow up of 38.3 months. Overall response 
rate was 71.4%. PFS advantage was demonstrated in stage IIIA vs stage IIIB (median 38.6 
months vs 13.0 months, HR: 0.438, 95% CI: 0.209-0.917, p=0.025), N-stage N0-N2 vs N3 
(median 16.4 months vs 10.5 months, HR: 0.415, 95% CI: 0.201-0.855, p=0.014) and borderline 
advantage was seen in maximum standardized uptake value (SUVmax) of positive nodes<8 vs ³8 
(median 22.6 months vs 12.6 months, HR: 0.465, 95% CI 0.198-1.091, p=0.072). OS advantage 
was revealed in stage IIIA vs stage IIIB (not reached vs 22.7 months, HR: 0.245, 95% CI: 0.085-
0.706, p=0.005) and SUVmax <8 vs ³8 (not reached vs 18.5 months, HR: 0.354, 95% CI: 0.122-
1.029, p=0.047). Cox proportional hazard model showed that stage IIIA (p=0.011), planning 
target volume (PTV) (p=0.003) and N0-N2 disease (p=0.007) were predictors of PFS while stage 
IIIA (p<0.001) and SUVmax of positive lymph nodes<8 (p=0.029) were predictors of OS. Dose 
of radiotherapy was neither a predictor of PFS and OS. Grade³2 radiation fibrosis was noted in 5 
(8.9%) patients. There was no treatment-related mortality. CONCLUSIONS: Our study result was 
highly comparable with previously published international results. Stage IIIA disease and 
SUVmax of positive lymph nodes<8 are significant predictors of OS. PET-CT scan at the time of 
diagnosis is useful in stratification of patients into favorable and unfavorable groups. 
